<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tranexamic acid for patients with nasal haemorrhage (epistaxis) - Joseph, J - 2018 | Cochrane Library</title> <meta content="Tranexamic acid for patients with nasal haemorrhage (epistaxis) - Joseph, J - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004328.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tranexamic acid for patients with nasal haemorrhage (epistaxis) - Joseph, J - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004328.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004328.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Tranexamic acid for patients with nasal haemorrhage (epistaxis)" name="citation_title"/> <meta content="Jonathan Joseph" name="citation_author"/> <meta content="Royal National Throat, Nose and Ear Hospital" name="citation_author_institution"/> <meta content="jajoseph@doctors.org.uk" name="citation_author_email"/> <meta content="Pablo Martinez‐Devesa" name="citation_author"/> <meta content="John Radcliffe Hospital ‐ West Wing" name="citation_author_institution"/> <meta content="Jenny Bellorini" name="citation_author"/> <meta content="Nuffield Department of Surgical Sciences, University of Oxford" name="citation_author_institution"/> <meta content="Martin J Burton" name="citation_author"/> <meta content="Cochrane UK" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD004328.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2019/12/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004328.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004328.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004328.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Administration, Topical; Antifibrinolytic Agents [administration &amp; dosage, adverse effects, *therapeutic use]; Blood Transfusion [statistics &amp; numerical data]; Epinephrine [therapeutic use]; Epistaxis [*drug therapy]; Length of Stay; Lidocaine [therapeutic use]; Phenylephrine [therapeutic use]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention [statistics &amp; numerical data]; Tranexamic Acid [administration &amp; dosage, adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004328.pub3&amp;doi=10.1002/14651858.CD004328.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004328\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004328\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","zh_HANS","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004328.pub3",title:"Tranexamic acid for patients with nasal haemorrhage (epistaxis)",firstPublishedDate:"Dec 31, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane ENT Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004328.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004328.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004328.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004328.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004328.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004328.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004328.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004328.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004328.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004328.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15052 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004328.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0045"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0046"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-sec-0111"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/appendices#CD004328-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/table_n/CD004328StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/table_n/CD004328StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Tranexamic acid for patients with nasal haemorrhage (epistaxis)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#CD004328-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jonathan Joseph</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#CD004328-cr-0003">Pablo Martinez‐Devesa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#CD004328-cr-0004">Jenny Bellorini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information#CD004328-cr-0005">Martin J Burton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information/en#CD004328-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 December 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004328.pub3">https://doi.org/10.1002/14651858.CD004328.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004328-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004328-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004328-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004328-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004328-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD004328-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004328-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004328-abs-0001" lang="en"> <section id="CD004328-sec-0001"> <h3 class="title" id="CD004328-sec-0001">Background</h3> <p>Epistaxis (nosebleed) most commonly affects children and the elderly. The majority of episodes are managed at home with simple measures. In more severe cases medical intervention is required to either cauterise the bleeding vessel, or to pack the nose with various materials. Tranexamic acid is used in a number of clinical settings to stop bleeding by preventing clot breakdown (fibrinolysis). It may have a role in the management of epistaxis as an adjunct to standard treatments, reducing the need for further intervention. </p> </section> <section id="CD004328-sec-0002"> <h3 class="title" id="CD004328-sec-0002">Objectives</h3> <p>To determine the effects of tranexamic acid (oral, intravenous or topical) compared with placebo, no additional intervention or any other haemostatic agent in the management of patients with epistaxis. </p> </section> <section id="CD004328-sec-0003"> <h3 class="title" id="CD004328-sec-0003">Search methods</h3> <p>The Cochrane ENT Information Specialist searched the Cochrane ENT Register (via CRS Web); Central Register of Controlled Trials (CENTRAL) (via CRS Web); PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 29 October 2018. </p> </section> <section id="CD004328-sec-0004"> <h3 class="title" id="CD004328-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of tranexamic acid (in addition to usual care) compared with usual care plus placebo, usual care alone or usual care plus any other haemostatic agent, to control epistaxis in adults or children. </p> </section> <section id="CD004328-sec-0005"> <h3 class="title" id="CD004328-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by Cochrane. The primary outcomes were control of epistaxis: re‐bleeding (as measured by the proportion of patients re‐bleeding within a period of up to 10 days) and significant adverse effects (seizures, thromboembolic events). Secondary outcomes were control of epistaxis as measured by the time to stop initial bleeding (the proportion of patients whose bleeding is controlled within a period of up to 30 minutes); severity of re‐bleeding (as measured by (a) the proportion of patients requiring any further intervention and (b) the proportion of patients requiring blood transfusion); length of hospital stay and other adverse effects. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in <i>italics</i>. </p> </section> <section id="CD004328-sec-0006"> <h3 class="title" id="CD004328-sec-0006">Main results</h3> <p>We included six RCTs (692 participants). The overall risk of bias in the studies was low. Two studies assessed oral administration of tranexamic acid, given regularly over several days, and compared it to placebo. In the other four studies, a single application of topical tranexamic acid was compared with placebo (one study) and a combination of epinephrine and lidocaine or phenylephrine (three studies). All participants were adults. </p> <p><b><i>Tranexamic acid versus placebo</i> </b> </p> <p>For our primary outcome, control of epistaxis: re‐bleeding (proportion re‐bleeding within 10 days), we were able to pool data from three studies. The pooled result demonstrated a benefit of tranexamic acid compared to placebo, the risk of re‐bleeding reducing from 67% to 47% (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.56 to 0.90; three studies; 225 participants; <i>moderate‐quality evidence</i>). </p> <p>When we compared the effects of oral and topical tranexamic acid separately the risk of re‐bleeding with <b>oral</b> tranexamic acid reduced from 69% to 49%, RR 0.73 (95% CI 0.55 to 0.96; two studies, 157 participants; <i>moderate‐quality evidence</i>) and with <b>topical</b> tranexamic acid it reduced from 66% to 43%, RR 0.66 (95% CI 0.41 to 1.05; single study, 68 participants). We rated the quality of evidence provided by the single study as <i>low</i>, therefore it is uncertain whether topical tranexamic acid is effective in stopping bleeding in the 10‐day period after a single application. </p> <p>No study specifically sought to identify and report our primary outcome: significant adverse effects (i.e. seizures, thromboembolic events). </p> <p>The secondary outcome time to stop initial bleeding (proportion with bleeding controlled within 30 minutes) was measured in one study using topical tranexamic acid and there was no evidence of a difference at 30 minutes (RR 0.79, 95% CI 0.56 to 1.11; 68 participants; <i>low‐quality evidence</i>). </p> <p>No studies reported the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation). </p> <p>One study of oral tranexamic acid reported the proportion of patients requiring blood transfusion and found no difference between groups: 5/45 (11%) versus 6/44 (14%) (RR 0.81, 95% CI 0.27 to 2.48; 89 participants; <i>low‐quality evidence</i>). </p> <p>Two studies reported hospital length of stay. One study reported a significantly shorter stay in the oral tranexamic acid group (mean difference (MD) ‐1.60 days, 95% CI ‐2.49 to ‐0.71; 68 participants). The other study found no evidence of a difference between the groups. </p> <p><b><i>Tranexamic acid versus other haemostatic agents</i> </b> </p> <p>When we pooled the data from three studies the proportion of patients whose bleeding stopped within 10 minutes was significantly higher in the topical tranexamic acid group compared to the group receiving another haemostatic agent (70% versus 30%: RR 2.35, 95% CI 1.90 to 2.92; 460 participants) (<i>moderate‐quality evidence</i>). </p> <p><b><i>Adverse effects across all studies</i> </b> </p> <p>Five studies recorded 'adverse effects' in a general way. None found any difference between the groups in the occurrence of minor adverse effects (e.g. mild nausea and diarrhoea, 'bad taste' of gel). In one study a patient developed a superficial thrombophlebitis of both legs following discharge, however it is not reported in which group this occurred. No "other serious adverse effect" was reported in any study. </p> </section> <section id="CD004328-sec-0007"> <h3 class="title" id="CD004328-sec-0007">Authors' conclusions</h3> <p>We found <i>moderate‐quality evidence</i> that there is probably a reduction in the risk of re‐bleeding with the use of either oral or topical tranexamic acid in addition to usual care in adult patients with epistaxis, compared to placebo with usual care. However, the quality of evidence relating solely to <i>topical</i> tranexamic acid was low (one study only), so we are uncertain whether or not <i>topical</i> tranexamic acid is effective in stopping bleeding in the 10‐day period after a single application. We found <i>moderate‐quality evidence</i> that topical tranexamic acid is probably better than other topical agents in stopping bleeding in the first 10 minutes. </p> <p>There have been only three RCTs on this subject since 1995. Since then there have been significant changes in nasal cauterisation and packing techniques (for example, techniques including nasal endoscopy and more invasive approaches such as endoscopic sphenopalatine artery ligation). New trials would inform us about the effectiveness of tranexamic acid in light of these developments. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004328-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004328-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004328-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004328-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004328-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004328-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004328-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD004328-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004328-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004328-abs-0003" lang="en"> <h3>Tranexamic acid to help treat nosebleeds (epistaxis)</h3> <p><b>Background</b> </p> <p>Nosebleeds are a very common condition, with the majority of those affected either children or those over the age of 60. They usually stop on their own or by simply compressing the nose with fingers, although a small number require medical attention. This will involve either cauterising (sealing) the bleeding vessel, if it can be seen, or packing the inside of the nose with a material to cause pressure to build up and stop the bleeding ('usual care'). Occasionally bleeding continues despite these measures, or it restarts having initially been controlled. This can lead to a prolonged hospital stay and the possibility of further procedures such as repacking with a different type of nasal pack or an operation. </p> <p>Tranexamic acid is a drug that is known to help promote blood clotting by preventing a natural process called fibrinolysis (dissolution of a clot). It is already used in a number of situations where bleeding is a significant worry, such as after heart surgery or major trauma. It can be given by mouth (orally), directly to the bleeding site (topically) or by injection into a vein (intravenously). </p> <p><b>Study characteristics</b> </p> <p>We searched for randomised controlled trials in patients of any age with nosebleed requiring intervention. Patients were treated with tranexamic acid (in addition to usual care) compared to placebo, no treatment or any other agent used to stop bleeding. We found six studies that met our inclusion criteria, with a total of 692 participants. Two studies used oral administration of tranexamic acid and four used topical administration. All participants in the studies were adults. Three of the six studies were conducted over 20 years ago. </p> <p><b>Key results</b> </p> <p>Three studies measured re‐bleeding within 10 days. When we combined the results we found that fewer patients who were given either oral or topical tranexamic acid had further episodes of re‐bleeding following an initial nosebleed compared to those treated with usual care. </p> <p>The time to stop initial bleeding (control of bleeding within 30 minutes) was measured in four studies. In three studies the proportion of patients whose bleeding stopped within 10 minutes was significantly higher in the group receiving topical tranexamic acid compared to the group receiving a different drug (topical epinephrine and lidocaine or phenylephrine). In the other study there was no significant difference at 30 minutes when topical tranexamic acid was compared with placebo. </p> <p>No studies reported the proportion of patients requiring any further intervention (e.g. repacking, surgery). </p> <p>Only one study of oral tranexamic acid reported the proportion of patients requiring a blood transfusion and there was no evidence of a difference between the groups. </p> <p>Length of hospital stay was reported in two studies. One study reported a significantly shorter stay in the oral tranexamic acid group, while the other found no evidence of a difference. </p> <p>Five studies mention recording "adverse effects". None found any difference between the groups in the occurrence of minor adverse effects (e.g. mild nausea and diarrhoea, 'bad taste' of gel). In one study a patient did develop a superficial thrombophlebitis (inflammation and a blood clot in a vein near the surface of the skin) of both legs following discharge, but the study did not report in which treatment group this happened. No serious adverse event was seen in any of the studies. </p> <p><b>Quality of the evidence and conclusions</b> </p> <p>Overall, the risk of bias in the six studies was low. We graded the quality of the evidence for the main outcome (control of epistaxis: re‐bleeding within 10 days) as moderate, which means that further research is likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate. In light of this and the fact that 'usual care' has changed, with the development of more modern nasal cauterisation and packing techniques, since three of the included studies were carried out, there remains uncertainty about the role of tranexamic acid in the treatment of patients with epistaxis. Newer research into the effect of tranexamic acid as a treatment for nosebleeds would inform future management decisions for this condition. </p> <p>The evidence in this review is up to date to October 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004328-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004328-sec-0117"></div> <h3 class="title" id="CD004328-sec-0118">Implications for practice</h3> <section id="CD004328-sec-0118"> <p>Tranexamic acid probably reduces the risk of patients with epistaxis having further bleeding episodes. We found moderate‐quality evidence that there may be a reduction in the risk of re‐bleeding from 67% to 47% with the use oral or topical tranexamic acid in addition to usual care in adult patients with epistaxis, compared to placebo with usual care. Low‐quality evidence suggests that topical tranexamic acid may make little or no difference to the control of bleeding in the first 30 minutes after its application. In three studies, the proportion of patients whose bleeding stopped within 10 minutes was significantly higher in the topical tranexamic acid group compared with other haemostatic agents (topical epinephrine/lidocaine combination or phenylephrine) (moderate‐quality evidence). No significant adverse effects of treatment were reported in the included studies. </p> </section> <h3 class="title" id="CD004328-sec-0119">Implications for research</h3> <section id="CD004328-sec-0119"> <p>This review has found evidence to suggest that there is probably a reduction in re‐bleeding episodes when using oral or topical tranexamic acid in addition to 'usual care'. However, although the latest randomised controlled trials were published between 2013 and 2018, all the other trials were conducted before 1995. Further randomised controlled trials, on similar cohorts of patients, attending hospital with epistaxis, using modern nasal cauterisation and packing techniques (for example, techniques including nasal endoscopy and more invasive approaches such as endoscopic sphenopalatine artery ligation), and investigating the use of tranexamic acid in light of these advances, compared to 'usual care' alone, would be informative and improve our certainty about any treatment effect. Trials may specifically look at the effectiveness and safety of topical tranexamic acid. It has been suggested that the use of this formulation may be associated with fewer adverse events (due to an absence of systemic absorption). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004328-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004328-sec-0036"></div> <div class="table" id="CD004328-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with nasal haemorrhage (epistaxis)<br/> <b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> placebo plus usual care or usual care alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens?</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo plus usual care or usual care alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days</p> <p>All treatments (topical and oral)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.56 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranexamic acid probably leads to fewer re‐bleeding events compared to placebo at 10 days </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/> (376 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days<br/> Oral treatment only </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.55 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oral tranexamic acid probably leads to fewer re‐bleeding events compared to placebo at 10 days </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>679 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>496 per 1000<br/> (373 to 652) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days<br/> Topical application (10% gel) only </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.41 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the chance of re‐bleeding in the 10 days after a single topical application of tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000<br/> (270 to 691) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: time to stop initial bleeding<br/> (proportion of patients whose bleeding is controlled in ≤ 30 minutes) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79 (0.56 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the proportion of patients whose epistaxis was controlled in the first 30 minutes </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000 (336 to 666)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.27 to 2.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the proportion of patients needing a blood transfusion </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (37 to 338) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported a significantly shorter stay in the oral tranexamic acid group (MD ‐1.60 days, 95% CI ‐2.49 to ‐0.71; 68 participants). The other study found no evidence of a difference between the groups. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not pool the data due to heterogeneity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: serious or other</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study specifically sought to identify and report our primary outcome, the significant adverse effects of seizure and thromboembolism. All the studies recorded "adverse effects" in a general way and there were no significant differences between groups in the occurrence of the minor adverse effects noted (e.g. mild nausea and diarrhoea, 'bad taste' of gel). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Imprecision: downgraded by one level ‐ small number of studies (or single study) and small number of participants (per study).<br/> <sup>2</sup>Study limitations (risk of bias): downgraded by one level due to study risk of bias (differences in baseline severity of bleeding that could affect the result in <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; selective reporting in <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004328-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with nasal haemorrhage (epistaxis)<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> other haemostatic agent </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other haemostatic agent</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>We could not assess this outcome due to differences between the intervention and control arms (other than the application of tranexamic acid) after the first 10 minutes of treatment in <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> (see <a href="#CD004328-sec-0074">Included studies</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35<br/> (1.90 to 2.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>460<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranexamic acid probably leads to a higher proportion of participants with bleeding controlled within 10 minutes. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000<br/> (568 to 872) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not assessed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>We could not assess this outcome due to differences between the intervention and control arms (other than the application of tranexamic acid) after the first 10 minutes of treatment (see <a href="#CD004328-sec-0074">Included studies</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: serious or other</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study specifically sought to identify and report our primary outcome, the significant adverse effects of seizure and thromboembolism. Five of the studies recorded "adverse effects" in a general way and there were no significant differences between groups in the occurrence of the minor adverse effects noted (e.g. mild nausea and diarrhoea, 'bad taste' of gel). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to study limitations (risk of bias ‐ no blinding) (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). </p> <p><sup>2</sup>Downgraded by one level for imprecision (wide confidence interval). </p> <p><sup>3</sup>Upgraded by one level ‐ large effect size (RR 2.35). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004328-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004328-sec-0037"></div> <section id="CD004328-sec-0038"> <h3 class="title" id="CD004328-sec-0038">Description of the condition</h3> <p>Epistaxis (nosebleed) is extremely common. It has a pronounced bimodal distribution, being common in childhood and then becoming less frequent before the incidence rises again in the sixth decade (<a href="./references#CD004328-bbs2-0036" title="McGarryGW . Epistaxis. In: GleesonM , BrowningGG , BurtonMJ , ClarkeR , HibbertJ , JonesNS , et al. editor(s). Scott‐Brown's Otolaryngology, Head and Neck Surgery. 7th Edition. Vol. 2, Chapter 126, London: Edward Arnold, 2008:1596‐606. ">McGarry 2008</a>). Its prevalence in random samples of the population was found in one study to be 10% to 12% at any given time (<a href="./references#CD004328-bbs2-0042" title="ShaheenOH . Epistaxis in the Middle Aged and Elderly [Thesis]. London: University of London, 1967. ">Shaheen 1967</a>). The cause of epistaxis is unknown in 70% to 80% of cases (idiopathic epistaxis) (<a href="./references#CD004328-bbs2-0044" title="StellPM . Epistaxis. Clinical Otolaryngology1977;2:263‐73. ">Stell 1977</a>). However, epistaxis may be secondary to a number of causes such as surgery, trauma, hypertension, coagulation abnormalities, hereditary haemorrhagic telangiectasia and the use of medications such as aspirin and warfarin (<a href="./references#CD004328-bbs2-0036" title="McGarryGW . Epistaxis. In: GleesonM , BrowningGG , BurtonMJ , ClarkeR , HibbertJ , JonesNS , et al. editor(s). Scott‐Brown's Otolaryngology, Head and Neck Surgery. 7th Edition. Vol. 2, Chapter 126, London: Edward Arnold, 2008:1596‐606. ">McGarry 2008</a>). </p> <p>Most epistaxis is self‐limiting or settles with simple measures such as compression (pinching the nose for example), and is ideally managed at home without further medical interference. Patients with more severe bleeding may require medical attention. Two basic methods are used: cauterisation to seal the bleeding vessel if it can be seen and, when this is not possible, various materials may be used to pack the nose to arrest the blood flow. In anterior epistaxis, which is the most common type, a bleeding point is often visible and can be cauterised under local anaesthetic by either a locally applied chemical such as silver nitrate or by electrocautery (hot wire). In some cases this is not sufficient and nasal packing is required with materials such as ribbon gauze, nasal tampons, balloons or inflatable packs. Posterior epistaxis is more common in older adults with hypertension and arteriosclerosis. In these cases a bleeding point is often not identified and nasal packing is necessary. This packing usually stays in for one to two days and applies pressure to the bleeding site thereby stopping the bleeding. </p> <p>Re‐bleeding may occur after initial management, which often results in a longer hospital stay and further treatments including repeat nasal packing, surgery or embolisation. </p> <p>If bleeding persists or recurs despite nasal packing then surgical intervention may be necessary and if the blood loss is great, transfusion may be necessary. </p> <p>Patients admitted with a severe epistaxis, whether anterior or posterior, may face significant morbidity. Nasal packing is uncomfortable. There is also a very small risk of death from a number of causes including the epistaxis itself (when uncontrollable) and the effects of treatments. For example, nasal packing can lead to hypoxia and, if a general anaesthetic is required as part of the treatment, this also carries small but significant risks. </p> </section> <section id="CD004328-sec-0039"> <h3 class="title" id="CD004328-sec-0039">Description of the intervention</h3> <p>Tranexamic acid is an anti‐fibrinolytic agent, used to prevent or treat bleeding in a wide variety of clinical situations. It can be administered orally or intravenously, or applied topically. It is contra‐indicated in patients with thromboembolic disease such as stroke and heart attack. </p> </section> <section id="CD004328-sec-0040"> <h3 class="title" id="CD004328-sec-0040">How the intervention might work</h3> <p>Tranexamic acid stabilises blood clots by competitively inhibiting the binding of plasminogen to fibrin preventing fibrinolysis. This antifibrinolytic effect means that it is routinely used to reduce excessive bleeding and to prevent re‐bleeding in many clinical situations (<a href="./references#CD004328-bbs2-0035" title="KerK , EdwardsP , PerelP , ShakurH , RobertsI . Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta‐analysis. BMJ2012;344:e3054. ">Ker 2012</a>; <a href="./references#CD004328-bbs2-0041" title="RobertsI , ShakurH , CoatsT , HuntB , BalogunE , BarnetsonL , et al. The CRASH‐2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technology Assessment (Winchester, England)2013;17(10):1‐79. ">Roberts 2013</a>). For example, it is used following cardiac surgery when cardiopulmonary bypass is used and in acute upper gastrointestinal bleeding (<a href="./references#CD004328-bbs2-0032" title="DunnCJ , GoaKL . Tranexamic acid: a review of its use in surgery and other indications. Drugs1999;57(6):1005‐32. ">Dunn 1999</a>). </p> <p>Tranexamic acid may therefore have a role to play in the management of epistaxis as an adjunct to usual therapies. It may have roles in (a) stopping initial bleeding, and (b) preventing or reducing the frequency and/or severity of re‐bleeding. This will reduce the need for further interventions with all their attendant risks. </p> <section id="CD004328-sec-0041"> <h4 class="title">Tranexamic acid to stop or minimise initial bleeding</h4> <p>In patients with epistaxis, tranexamic acid may help stop bleeding at the time of initial administration (or very shortly thereafter), preventing the need for more invasive treatments such as cautery and nasal packing. It is uncertain whether a single dose (or a very short period of treatment) might result in a more rapid resolution of the patient's condition with fewer re‐bleeding episodes and the need for fewer interventions in a 'recovery' period lasting several days. </p> <p>The initiation of a course of tranexamic acid treatment destined to last several days may have a similar effect. </p> </section> <section id="CD004328-sec-0042"> <h4 class="title">Tranexamic acid to prevent re‐bleeding</h4> <p>Tranexamic acid may be prescribed regularly, over a number of days after the initial epistaxis, in order to achieve similar ends: that is, more rapid resolution of the patient's condition with fewer re‐bleeding episodes and the need for fewer interventions in that period. </p> </section> <section id="CD004328-sec-0043"> <h4 class="title">Adverse effects</h4> <p>The most common adverse events are gastrointestinal (for example, nausea, diarrhoea and abdominal cramping), which are mild and uncommon (<a href="./references#CD004328-bbs2-0040" title="RobbPJ . Tranexamic acid ‐ a useful drug in ENT surgery?. Journal of Laryngology and Otology2014;128:574‐9. ">Robb 2014</a>). However, thromboembolic events (<a href="./references#CD004328-bbs2-0037" title="NishiharaS , HamadaM . Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?. The Bone &amp; Joint Journal2015;97‐B(4):458‐62. ">Nishihara 2015</a>) and seizures (<a href="./references#CD004328-bbs2-0043" title="SharmaV , KatznelsonR , JerathA , Garrido‐OlivaresL , CarrollJ , RaoV , et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia2014;69(2):124‐30. ">Sharma 2014</a>) have been reported (although these two studies do not evaluate patients with epistaxis or receiving tranexamic acid in doses similar to patients with epistaxis). </p> </section> </section> <section id="CD004328-sec-0044"> <h3 class="title" id="CD004328-sec-0044">Why it is important to do this review</h3> <p>There is uncertainty about the role of tranexamic acid in the management of patients with epistaxis. A recent audit of epistaxis management in the UK analysed the data from 1122 patients and found that tranexamic acid was used in 8.2% of cases (<a href="./references#CD004328-bbs2-0045" title="INTEGRATE (The National ENT Trainee Research Network), National ENT Trainee Research Network. Epistaxis 2016: national audit of management. Journal of Laryngology and Otology2017;131(12):1131‐41. [DOI: 10.1017/S002221511700202X; PUBMED: 29280693] ">UK Epistaxis Audit 2017</a>). Time to haemostasis was longer and re‐bleeding rates were higher in these patients; however, the number of patients was small and they had a "higher degree of illness". A consensus document on the hospital management of epistaxis (<a href="./references#CD004328-bbs2-0031" title="INTEGRATE (The National ENT Trainee Research Network), National ENT Trainee Research Network. The British Rhinological Society multidisciplinary consensus recommendations on the hospital management of epistaxis. Journal of Laryngology and Otology2017;131(12):1142‐56. ">BRS 2017</a>) highlighted the inconsistent findings from a systematic review (<a href="./references#CD004328-bbs2-0046" title="WilliamsA , BiffenA , PilkingtonN , ArrickL , WilliamsRJ , SmithME , et al. Haematological factors in the management of adult epistaxis: systematic review. Journal of Laryngology and Otology2017;131(12):1093‐107. [DOI: 10.1017/S0022215117002067; PUBMED: 29280698] ">Williams 2017</a>) and therefore did not recommend the use of either oral or topical tranexamic acid, except in relevant cases (i.e. following national guidelines on the use of tranexamic acid in major haemorrhage). Further studies are, however, ongoing and their findings may expand the evidence base (<a href="./references#CD004328-bbs2-0028" title="ISRCTN34153772 . Novel use of TXA to reduce the need for nasal packing in epistaxis. http://www.isrctn.com/ISRCTN34153772 (first received 1 June 2017). ">ISRCTN34153772</a>; <a href="./references#CD004328-bbs2-0029" title="NCT02930941 . Topical intranasal tranexamic acid for epistaxis in the emergency department. https://clinicaltrials.gov/ct2/show/NCT02930941 (first received 12 October 2016). ">NCT02930941</a>; <a href="./references#CD004328-bbs2-0030" title="NCT03360045 . The evaluation of effectiveness of nasal compression with tranexamic acid compared to simple nasal compression and Merocel packing. https://clinicaltrials.gov/ct2/show/NCT03360045 (first received 2 December 2017). [NCT03360045] ">NCT03360045</a>). </p> <p>An up‐to‐date Cochrane Review, which can be updated as further studies are completed, is warranted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004328-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004328-sec-0045"></div> <p>To determine the effects of tranexamic acid (oral, intravenous or topical) compared with placebo, no additional intervention or any other haemostatic agent in the management of patients with epistaxis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004328-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004328-sec-0046"></div> <section id="CD004328-sec-0047"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004328-sec-0048"> <h4 class="title">Types of studies</h4> <p>We included studies with the following design characteristics:</p> <p> <ul id="CD004328-list-0001"> <li> <p>Randomised controlled trials (RCTs) including cluster‐randomised trials.</p> </li> <li> <p>Patients were followed up for at least seven days.</p> </li> </ul> </p> </section> <section id="CD004328-sec-0049"> <h4 class="title">Types of participants</h4> <p>Patients of any age with epistaxis requiring intervention by a healthcare professional.</p> <section id="CD004328-sec-0050"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD004328-list-0002"> <li> <p>Patients with a clotting or bleeding disorder, sinonasal malignancy and chronic inflammatory nasal conditions. </p> </li> </ul> </p> </section> </section> <section id="CD004328-sec-0051"> <h4 class="title">Types of interventions</h4> <p>Tranexamic acid in any formulation, delivered orally, intravenously or topically.</p> <p>If other interventions were used at the start of treatment, when tranexamic acid or placebo was given or first started, these should have been used in both treatment arms. Allowed co‐interventions included cautery and nasal packing. </p> <p>The comparators were:</p> <p> <ul id="CD004328-list-0003"> <li> <p>placebo;</p> </li> <li> <p>no treatment;</p> </li> <li> <p>any other haemostatic agent.</p> </li> </ul> </p> <p>After the start of treatment, patients may require further interventions to control re‐bleeding. These include: cauterisation, nasal packing, surgery and embolisation. </p> <p>The main comparison pair was:</p> <p> <ul id="CD004328-list-0004"> <li> <p>tranexamic acid <i>versus</i> placebo or no treatment. </p> </li> </ul> </p> <p>A second comparison pair was:</p> <p> <ul id="CD004328-list-0005"> <li> <p>tranexamic <i>versus</i> any other haemostatic agent. </p> </li> </ul> </p> <p>For a more detailed description of how we planned to group the interventions together for analysis see <a href="#CD004328-sec-0068">Subgroup analysis and investigation of heterogeneity</a>. </p> </section> <section id="CD004328-sec-0052"> <h4 class="title">Types of outcome measures</h4> <p>We analysed the following outcomes in the review, but we did not use them as a basis for including or excluding studies. </p> <section id="CD004328-sec-0053"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004328-list-0006"> <li> <p>Control of epistaxis: re‐bleeding, as measured by the proportion of patients re‐bleeding within a period of up to 10 days (minimum five days). </p> </li> <li> <p>Significant adverse effects: seizures, thromboembolic events.</p> </li> </ul> </p> </section> <section id="CD004328-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004328-list-0007"> <li> <p>Control of epistaxis: time to stop initial bleeding (as measured by the proportion of patients whose bleeding is controlled within 30 minutes). </p> </li> <li> <p>Severity of re‐bleeding, as measured by:</p> <ul id="CD004328-list-0008"> <li> <p>the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation) within 10 days; </p> </li> <li> <p>the proportion of patients requiring blood transfusion within 10 days.</p> </li> </ul> </li> <li> <p>Length of hospital stay in days.</p> </li> <li> <p>Other adverse effects.</p> </li> </ul> </p> </section> </section> </section> <section id="CD004328-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <p>The Cochrane ENT Information Specialist conducted systematic searches for randomised controlled trials and controlled clinical trials. There were no language, publication year or publication status restrictions. The date of the search was 29 October 2018. </p> <section id="CD004328-sec-0056"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched:</p> <p> <ul id="CD004328-list-0009"> <li> <p>the Cochrane ENT Register (searched via CRS Web 29 October 2018);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (searched via CRS Web 29 October 2018); </p> </li> <li> <p>PubMed (1946 to 29 October 2018);</p> </li> <li> <p>Ovid EMBASE (1974 to 29 October 2018);</p> </li> <li> <p>Ovid CAB Abstracts (1910 to 29 October 2018);</p> </li> <li> <p>EBSCO CINAHL (1982 to 29 October 2018);</p> </li> <li> <p>LILACS, <a href="http://lilacs.bvsalud.org" target="_blank">lilacs.bvsalud.org</a> (searched 29 October 2018); </p> </li> <li> <p>KoreaMed, <a href="http://www.koreamed.org" target="_blank">www.koreamed.org</a> (searched 29 October 2018); </p> </li> <li> <p>IndMed, <a href="http://www.indmed.nic.in" target="_blank">www.indmed.nic.in</a> (searched 29 October 2018); </p> </li> <li> <p>PakMediNet, <a href="http://www.pakmedinet.com" target="_blank">www.pakmedinet.com</a> (searched 29 October 2018); </p> </li> <li> <p>Web of Knowledge, Web of Science (1945 to 29 October 2018);</p> </li> <li> <p>CNKI, <a href="http://www.cnki.com.cn" target="_blank">www.cnki.com.cn</a> (searched via Google Scholar 29 October 2018); </p> </li> <li> <p>ClinicalTrials.gov, (searched via CRS Web 29 October 2018);</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), <a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a> (searched 29 October 2018). </p> </li> </ul> </p> <p>In searches prior to 2012, we also searched BIOSIS Previews 1926 to November 2012.</p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). Search strategies for major databases including CENTRAL are provided in <a href="./appendices#CD004328-sec-0123">Appendix 1</a>. </p> </section> <section id="CD004328-sec-0057"> <h4 class="title">Searching other resources</h4> <p>We scanned the reference lists of identified publications for additional trials and contacted trial authors where necessary. In addition, the Information Specialist searched PubMed to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Information Specialist also ran non‐systematic searches of Google Scholar to retrieve grey literature and other sources of potential trials. </p> </section> </section> <section id="CD004328-sec-0058"> <h3 class="title" id="CD004328-sec-0058">Data collection and analysis</h3> <section id="CD004328-sec-0059"> <h4 class="title">Selection of studies</h4> <p>Two authors (JJ and PMD or JB and MB) independently scanned the search results to identify studies that loosely met the inclusion criteria. We then independently reviewed the full texts of the retrieved trials and applied the inclusion criteria. We resolved any differences between the authors in study selection through discussion and reaching a consensus. We documented our search and study selection process and depicted this graphically in a PRIMSA flowchart. </p> </section> <section id="CD004328-sec-0060"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from the studies using standardised data forms, allowing for an intention‐to‐treat analysis. The main data items that we extracted were: date, duration and setting for the study, number of participants, participant (baseline) characteristics (age, gender, other), type of 'usual care' provided, method of delivery and dosage of tranexamic acid and type of outcome measures used (see <a href="./appendices#CD004328-sec-0124">Appendix 2</a>). Where data were missing we attempted to contact the authors of the study to request the missing information. </p> </section> <section id="CD004328-sec-0061"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (JJ and PMD) undertook independent assessment of the risk of bias of the included studies. The following were taken into consideration, as guided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>): </p> <p> <ul id="CD004328-list-0010"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other sources of bias.</p> </li> </ul> </p> <p>We used the Cochrane 'Risk of bias' tool in RevMan 5 (<a href="./references#CD004328-bbs2-0039" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), which involves describing each of these domains as reported in the study and then assigning a judgement about the adequacy of each entry: low, high or unclear (or unknown) risk of bias. </p> </section> <section id="CD004328-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the effects of dichotomous outcomes (e.g. proportion of patients with re‐bleeding) as risk ratios (RR) with CIs. For the key outcomes that we presented in the 'Summary of findings' table, we also expressed the results as absolute numbers based on the pooled results and compared to the assumed risk. The assumed baseline risk is typically either (a) the median of the risks of the control groups in the included studies, this being used to represent a 'medium‐risk population' or, alternatively, (b) the average risk of the control groups in the included studies is used as the 'study population' (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). If a large number of studies were available, and where appropriate, we also planned to present additional data based on the assumed baseline risk in (c) a low‐risk population and (d) a high‐risk population. </p> <p>For continuous outcomes, we expressed treatment effects as a mean difference (MD) with standard deviation (SD). </p> </section> <section id="CD004328-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>If we had found cluster‐randomised trials, we would have analysed these according to the methods in section 16.3.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). </p> </section> <section id="CD004328-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We planned to undertake an intention‐to‐treat analysis where possible.</p> <p>We planned to contact study authors via email whenever the outcome of interest was not reported, if the methods of the study suggested that the outcome had been measured. We planned to do the same if not all data required for meta‐analysis had been reported, unless the missing data were standard deviations. If standard deviation data were not available, we planned to approximate these using the standard estimation methods from P values, standard errors or 95% CIs if these were reported as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). If it was impossible to estimate these, we would have contacted the study authors. </p> <p>Apart from imputations for missing standard deviations, we did not plan to conduct any other imputations. </p> </section> <section id="CD004328-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity (which may be present even in the absence of statistical heterogeneity) by examining the included studies for potential differences between them in the types of participants recruited, interventions or controls used or outcomes measured. In this review we anticipated that the intervention might have been used in two different ways: as a single treatment at the time of bleeding, or over a period following initial treatment to prevent re‐bleeding, or a combination of both. </p> <p>We assessed statistical heterogeneity using the Chi² test with P &lt; 0.05 indicating significance. We also used the I² statistic with the following thresholds for assessing the impact of the heterogeneity the pooled analyses: </p> <p> <ul id="CD004328-list-0011"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD004328-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias as between‐study publication bias (using funnel plots if sufficient studies were available) and as within‐study outcome reporting bias. There was sometimes insufficient information to judge the risk of selective reporting bias: we noted this as an 'unclear' risk of bias. </p> </section> <section id="CD004328-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We conducted all meta‐analyses using Review Manager 5.3 (<a href="./references#CD004328-bbs2-0039" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For dichotomous data, we analysed treatment differences as a risk ratio (RR) calculated using the Mantel‐Haenszel method. </p> <p>For continuous outcomes, we planned to pool mean values obtained at follow‐up and report a mean difference (MD). </p> <p>When statistical heterogeneity is low, random‐effects versus fixed‐effect methods yield trivial differences in treatment effects. However, when statistical heterogeneity is high, the random‐effects method provides a more conservative estimate of the difference. </p> </section> <section id="CD004328-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct the following subgroup analyses regardless of whether statistical heterogeneity was observed, as these may be effect modifiers: </p> <p> <ul id="CD004328-list-0012"> <li> <p>mode and timing of administration;</p> </li> <li> <p>patient age (children versus adults);</p> </li> <li> <p>setting (inpatient versus outpatient);</p> </li> <li> <p>site of nosebleed (anterior versus posterior).</p> </li> </ul> </p> <p>The various modes of administration of tranexamic acid are likely to affect the primary outcome in different ways. Topical administration is likely to have a faster effect but with a shorter duration. Oral and intravenous delivery will have a delayed onset (greater with oral administration than intravenous) but if repeated doses are given, the duration of effect will last at least as long as therapeutic doses are being administered. </p> </section> <section id="CD004328-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses to determine whether the findings were robust to the decisions made in the course of identifying, screening and analysing the trials. We planned to conduct sensitivity analysis for the following factors, whenever possible, and where applicable: </p> <p> <ul id="CD004328-list-0013"> <li> <p>impact of model chosen: fixed‐effect versus random‐effects model;</p> </li> <li> <p>risk of bias of included studies: excluding studies with high risk of bias (we defined these as studies that had a high risk of allocation concealment bias and a high risk of attrition bias (overall loss to follow‐up of 20%, differential follow‐up observed). </p> </li> </ul> </p> <p>If any of these investigations found a difference in the size of the effect or heterogeneity, we had planned to mention this in the <a href="#CD004328-sec-0098">Effects of interventions</a> section. </p> <section id="CD004328-sec-0070"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>Two authors (MB, JB) independently used the GRADE approach to rate the overall quality of evidence. The quality of evidence reflects the extent to which we are confident that an estimate of effect is correct and we applied this in the interpretation of results. There are four possible ratings: high, moderate, low and very low. A rating of high quality of evidence implies that we are confident in our estimate of effect and that further research is very unlikely to change our confidence in the estimate of effect. A rating of very low quality implies that any estimate of effect obtained is very uncertain. </p> <p>The GRADE approach rates evidence from RCTs which do not have serious limitations as high quality. However, several factors can lead to the downgrading of the evidence to moderate, low or very low. The degree of downgrading is determined by the seriousness of these factors: </p> <p> <ul id="CD004328-list-0014"> <li> <p>study limitations (risk of bias);</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness of evidence;</p> </li> <li> <p>imprecision; and</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>We included 'Summary of findings' tables for the comparisons of tranexamic acid <i>versus</i> placebo or no treatment and tranexamic acid <i>versus</i> other haemostatic agent, constructed according to the recommendations described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004328-bbs2-0033" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Handbook 2011</a>). </p> <p>We planned to include the following seven outcomes in the 'Summary of findings' table, but only those where data were available were actually included: </p> <p> <ul id="CD004328-list-0015"> <li> <p>Primary outcomes</p> <ul id="CD004328-list-0016"> <li> <p>Control of epistaxis: re‐bleeding (the proportion of patients re‐bleeding within a period of up to 10 days (minimum five days)). </p> </li> <li> <p>Significant adverse effects (seizures, thromboembolic events).</p> </li> </ul> </li> <li> <p>Secondary outcomes</p> <ul id="CD004328-list-0017"> <li> <p>Control of epistaxis: time to stop initial bleeding (the proportion of patients whose bleeding is controlled within 30 minutes). </p> </li> <li> <p>Severity of re‐bleeding, as measured by:</p> <ul id="CD004328-list-0018"> <li> <p>the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation) within 10 days); </p> </li> <li> <p>the proportion of patients requiring blood transfusion within 10 days).</p> </li> </ul> </li> <li> <p>Length of hospital stay in days.</p> </li> <li> <p>Other adverse effects.</p> </li> </ul> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004328-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004328-sec-0071"></div> <section id="CD004328-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD004328-sec-0073"> <h4 class="title">Results of the search</h4> <p>A total of 680 references were retrieved by the searches in October 2018. This reduced to 431 following de‐duplication and removal of clearly irrelevant references. We discarded 401 records in first‐level screening, leaving 30 references for further consideration. </p> <p>We excluded 21 studies (see <a href="#CD004328-sec-0088">Excluded studies</a> below and <a href="./references#CD004328-sec-0134" title="">Characteristics of excluded studies</a> for the reasons for exclusion). </p> <p>We identified three ongoing studies (see <a href="./references#CD004328-sec-0135" title="">Characteristics of ongoing studies</a>). No studies are awaiting assessment. </p> <p>We selected six studies for inclusion in the review.</p> <p>A PRISMA flow diagram depicting our search and selection process is shown in <a href="#CD004328-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004328-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD004328-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> </div> </section> <section id="CD004328-sec-0074"> <h4 class="title">Included studies</h4> <p>We included six studies with a total of 692 participants (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). Full details of the included studies are shown in the <a href="./references#CD004328-sec-0133" title="">Characteristics of included studies</a> table. </p> <section id="CD004328-sec-0075"> <h5 class="title">Design</h5> <p>Three of the included studies were randomised, placebo‐controlled and double‐blinded (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). Two studies were randomised, non‐placebo‐controlled, single‐blinded studies (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a> was a randomised, double‐blind, non‐placebo‐controlled study. </p> </section> <section id="CD004328-sec-0076"> <h5 class="title">Sample sizes</h5> <p>The number of participants in each study ranged from 68 to 216.</p> </section> <section id="CD004328-sec-0077"> <h5 class="title">Setting and participants</h5> <p>Included in the review are two inpatient studies (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>) and four outpatient studies (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). All participants were adults. Two studies were carried out in Sweden (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>), one in the UK (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>), and three in Iran (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). </p> <p>None of the studies documented the aetiology of the bleeds. In most cases there was no known cause (idiopathic). Three studies differentiated between anterior and posterior bleeds and only included those with anterior bleeding (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). </p> <p>In <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>, all participants were currently taking antiplatelet drugs (aspirin, clopidogrel or both). </p> </section> <section id="CD004328-sec-0078"> <h5 class="title">Interventions</h5> <section id="CD004328-sec-0079"> <h6 class="title">Oral tranexamic acid for 10 days</h6> <p>Both the inpatient studies used the same intervention, 1 g tranexamic acid tablets, three times daily, to begin within one hour of admission and to continue for 10 days, or placebo. They differed in what was termed 'usual care': </p> <p><a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> used packing alone, comprising a posterior Foley catheter in all cases with the addition of an anterior gauze tampon if necessary. Twelve to 24 hours after bleeding was stopped, the balloon was deflated and the catheter removed three to six hours later. If there was no further bleeding the gauze was removed until fresh blood was seen on it. Every three to six hours the gauze was removed in a similar fashion until it was all out. If there was a new severe bleed, the patients were re‐packed as above. </p> <p><a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a> treated the patients with a combination of nasal cautery and packing. Packing was removed 24 hours after bleeding had stopped and patients were discharged home a further 24 hours later if there was no further bleeding. </p> </section> <section id="CD004328-sec-0080"> <h6 class="title">Topical tranexamic acid (gel or liquid)</h6> <p><a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> treated the study participants with either 15 mL tranexamic acid gel (10%) or placebo gel applied locally to fill the nasal cavity. If bleeding was not arrested 30 minutes after gel application, traditional methods were used, which constituted 'usual care'. </p> <p>In the intervention group in both <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> a 15 cm cotton pledget soaked in the injectable form of tranexamic acid (500 mg in 5 mL) was placed in the nostril of the bleeding side. It was removed after bleeding was arrested. If "rescue treatment" was needed (presumably meaning that if bleeding did not stop) "routine anterior nasal packing and cautery" was used. The study participants in the control groups of both studies were treated with a cotton pledget soaked in epinephrine (1:100,000) and lidocaine (2%) to "decongest" the nose for 10 minutes followed by packing with several cotton pledgets coated in tetracycline on the bleeding side for three days. "Rescue treatment" for the control group in both studies consisted of nasal cautery. </p> <p>There are differences (or potential differences) between the intervention and control arms of the <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> studies <i>other than</i> the application of tranexamic acid after the first 10 minutes of treatment. In the first 10 minutes, the two groups in both studies had either tranexamic acid or epinephrine/lidocaine; thereafter, the control groups were all packed and the intervention groups may or may not have been. This means that from 10 minutes to three days, one comparator group ‐ the control group ‐ comprised participants all of whose noses were cauterised and packed, and the other group had an unknown proportion of participants (&lt; 100%) who were cauterised and packed. For this reason, <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> therefore contributed data only to the comparison tranexamic versus any other haemostatic agent, and only to one epistaxis‐related outcome (see below) and to adverse effects. </p> <p>In <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, the intervention group received 1 cc tranexamic acid (injection solution, 500 mg/5 mL) poured onto a cotton ball and inserted into each nasal cavity. The control group received 1 cc phenylephrine (phenylephrine HCL, nasal drops, 0.5%) administered in the same way. </p> </section> </section> <section id="CD004328-sec-0081"> <h5 class="title">Outcomes</h5> <section id="CD004328-sec-0082"> <h6 class="title">Control of epistaxis: re‐bleeding, as measured by the proportion of patients re‐bleeding within a period of up to 10 days (minimum five days) </h6> <p>Three studies recorded the number of patients with bleeding episodes over a 7‐ to 10‐day period (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). </p> </section> <section id="CD004328-sec-0083"> <h6 class="title">Significant adverse effects: seizures, thromboembolic events</h6> <p>Five of the studies referred to recording "adverse effects" and in <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>, <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>, <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> mention is made of looking for "severe" adverse effects but these were not pre‐defined. Separate data relating to any adverse effects in the first 10 minutes of the <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> studies were not available. <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a> did not report these. </p> </section> <section id="CD004328-sec-0084"> <h6 class="title">Control of epistaxis: time to stop initial bleeding (as measured by the proportion of patients whose bleeding is controlled within 30 minutes) </h6> <p>This outcome was evaluated in four studies: <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> (30 minutes) and <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> (10 minutes). </p> </section> <section id="CD004328-sec-0085"> <h6 class="title">Severity of re‐bleeding: as measured by a) the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation) within 10 days and b) the proportion of patients requiring blood transfusion within 10 days </h6> <p>None of the studies reported the proportion of patients requiring any further intervention. The proportion of patients requiring blood transfusion within 10 days was reported only in <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>. </p> </section> <section id="CD004328-sec-0086"> <h6 class="title">Length of hospital stay in days</h6> <p>Hospital stay was reported in <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> and <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>. </p> </section> <section id="CD004328-sec-0087"> <h6 class="title">Other adverse effects</h6> <p>As mentioned above, five studies mention recording "adverse effects".</p> </section> </section> </section> <section id="CD004328-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We excluded 21 studies. The reasons for exclusion are detailed in the <a href="./references#CD004328-sec-0134" title="">Characteristics of excluded studies</a> table. Several studies specifically studied tranexamic acid in participants with bleeding abnormalities such as hereditary haemorrhagic telangiectasia or in patients undergoing surgery (such as functional endoscopic sinus surgery or rhinoplasty). </p> <section id="CD004328-sec-0089"> <h5 class="title">Ongoing studies</h5> <p>We identified three ongoing placebo‐controlled randomised controlled trials of tranexamic acid in adults with epistaxis (<a href="./references#CD004328-bbs2-0028" title="ISRCTN34153772 . Novel use of TXA to reduce the need for nasal packing in epistaxis. http://www.isrctn.com/ISRCTN34153772 (first received 1 June 2017). ">ISRCTN34153772</a>; <a href="./references#CD004328-bbs2-0029" title="NCT02930941 . Topical intranasal tranexamic acid for epistaxis in the emergency department. https://clinicaltrials.gov/ct2/show/NCT02930941 (first received 12 October 2016). ">NCT02930941</a>; <a href="./references#CD004328-bbs2-0030" title="NCT03360045 . The evaluation of effectiveness of nasal compression with tranexamic acid compared to simple nasal compression and Merocel packing. https://clinicaltrials.gov/ct2/show/NCT03360045 (first received 2 December 2017). [NCT03360045] ">NCT03360045</a>). One has an estimated completion date of August 2018 and two are due to complete during 2019. (See <a href="./references#CD004328-sec-0135" title="">Characteristics of ongoing studies</a> for details). </p> </section> </section> </section> <section id="CD004328-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see the 'Risk of bias' table for each of the included studies (<a href="./references#CD004328-sec-0133" title="">Characteristics of included studies</a>), <a href="#CD004328-fig-0002">Figure 2</a> for a 'Risk of bias' graph (our judgements about each risk of bias item presented as percentages across all included studies) and <a href="#CD004328-fig-0003">Figure 3</a> for a 'Risk of bias' summary (our judgements about each risk of bias item for each included study). </p> <div class="figure" id="CD004328-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004328-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004328-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004328-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>As the Figures show, the overall risk of bias in the included studies is low. We found <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>, <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> and <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> to have a low risk of bias overall while <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> at high risk due to the absence of blinding. In <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>, the risk of attrition bias was unclear, but the number of participants lost to follow‐up was small. <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a> had an unclear risk of bias in several domains. </p> <section id="CD004328-sec-0091"> <h4 class="title">Allocation</h4> <section id="CD004328-sec-0092"> <h5 class="title">Sequence generation</h5> <p>We assessed all studies to be at low risk of selection bias with regard to sequence generation: all used randomisation, although two studies did not fully define how this was done (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>). </p> </section> <section id="CD004328-sec-0093"> <h5 class="title">Allocation concealment</h5> <p>For allocation concealment the risk of bias was low in three studies (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>) and unclear in three studies (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>). </p> </section> </section> <section id="CD004328-sec-0094"> <h4 class="title">Blinding</h4> <p>Three studies are described as 'double‐blind' and were at low risk of bias (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>); however, only <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a> fully defined how this was achieved. <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a> is described as a "double‐blind" study but no further details are provided (unclear risk of bias). </p> <p>It was not possible to blind the participants and those administering treatment in <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> due to clear differences in the methods of administration in the two groups (high risk of bias). Those analysing the data were blinded making these single‐blinded studies, however as only data from the first 10 minutes are used in this review, this is the only relevant time period for outcome assessment and evaluators at this point were not blind to the intervention. </p> </section> <section id="CD004328-sec-0095"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias in four studies was low (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). There is an unclear risk of bias due to a lack of data in one study (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>). In the other included study seven of 96 patients (7%) did not complete the course of treatment with no explanation given or comment on the distribution between groups (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). The data for these patients were removed from the analysis, which leads to an unclear risk of bias in this study. </p> </section> <section id="CD004328-sec-0096"> <h4 class="title">Selective reporting</h4> <p>All planned outcomes from the methods section in each study were reported on in <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>, <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>, <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>. <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> had low risk of bias due to robust outcome reporting strategies. There was some lack of clarity in the other three studies due to unclear methods of reporting of efficacy variables in one (<a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>), failure to report the number of units required for blood transfusion in another (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>), and general poor reporting of patient allocation in the last (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). In addition, several outcomes were not presented in the methods section of <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>, but are reported in the outcomes section (length of stay, number of blood transfusions and amount of blood transfused). </p> </section> <section id="CD004328-sec-0097"> <h4 class="title">Other potential sources of bias</h4> <p>There is an unclear risk of other bias. <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> noted bleeding resulting from the removal of nasal tampons but did not record these bleeds in their results. The overall effect of this is unknown. <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> noted that the baseline bleeding intensity was not equal between the treatment and control groups. They had applied a linear logistic model to data affected by this. Both <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> noted a difference between the treatment and control groups in the history of epistaxis. There were no concerns in the other study and therefore the risk of other bias is low (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). We detected no other sources of bias in <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, but our assessments are based on information extracted by a translator of this study, which is published in Farsi, so the judgement is unclear. </p> <p>None of the studies gave details of study funding. Only one study provided a statement about conflicts of interest and declared that there were none (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>). </p> </section> </section> <section id="CD004328-sec-0098"> <h3 class="title" id="CD004328-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD004328-tbl-0001"><b>Summary of findings for the main comparison</b> Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</a>; <a href="./full#CD004328-tbl-0002"><b>Summary of findings 2</b> Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</a> </p> <section id="CD004328-sec-0099"> <h4 class="title">Tranexamic acid versus placebo or usual care alone</h4> <section id="CD004328-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD004328-sec-0101"> <h6 class="title">Control of epistaxis: re‐bleeding (proportion of patients re‐bleeding within a period of up to 10 days) </h6> <p>See <a href="./full#CD004328-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>The primary outcome measure for this review was the effectiveness of tranexamic acid in the control of epistaxis. We measured this primarily as the proportion of patients who had an episode of re‐bleeding <i>within the first 10 days of treatment</i>. Combining the results of three studies with a total of 225 participants, we found moderate‐quality evidence that tranexamic acid probably reduces the risk of re‐bleeding (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.56 to 0.90, I² = 0%) (<a href="./references#CD004328-fig-0006" title="">Analysis 1.1</a>; <a href="#CD004328-fig-0004">Figure 4</a>). In the three studies tranexamic acid was used in two very different ways: as an oral treatment, given regularly over several days (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>) and as a 'one‐off' topical intervention at the patients' initial presentation (<a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>). Whilst the intervention may be very similar in terms of its composition and cellular mechanism of action, it is reasonable to assume that, overall, the way in which it is working as an agent to reduce bleeding is different. Therefore the subgroup analysis is especially pertinent. </p> <div class="figure" id="CD004328-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tranexamic acid versus placebo plus usual care or usual care alone, outcome: 1.1 Control of epistaxis: episodes of re‐bleeding over 10 days." data-id="CD004328-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tranexamic acid versus placebo plus usual care or usual care alone, outcome: 1.1 Control of epistaxis: episodes of re‐bleeding over 10 days. </p> </div> </div> </div> <p>When we compared the effects of <b>oral</b> tranexamic acid (RR 0.73, 95% CI 0.55 to 0.96; two studies, 157 participants, Analysis 1.1.1) (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>) and the effects of <b>topical</b> tranexamic acid (RR 0.66, 95% CI 0.41 to 1.05; single study, 68 participants, Analysis 1.1.2) (<a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>), both showed an effect similar to the overall result, although for the topical tranexamic acid group the 95% confidence interval included unity. We rated the quality of the evidence provided by this single study as <i>low</i>, and it is therefore uncertain whether or not topical tranexamic acid is effective in stopping bleeding in the period 10 days after a single application. A formal test of subgroup differences did not indicate any difference between the treatment effects of the two different methods of administration. </p> <p>We were unable to carry out any of our other planned subgroup analyses: patient age (children versus adults), setting (inpatient versus outpatient) or site of nosebleed (anterior versus posterior). </p> </section> <section id="CD004328-sec-0102"> <h6 class="title">Significant adverse effects: seizures, thromboembolic events</h6> <p>No study specifically sought to identify and report these particular adverse events, although all recorded 'adverse effects' in a general way. No significant adverse effects were reported in any study. </p> </section> </section> <section id="CD004328-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD004328-sec-0104"> <h6 class="title">Control of epistaxis: time to stop initial bleeding (as measured by the proportion of patients whose bleeding is controlled within 30 minutes) </h6> <p>We also measured control of epistaxis in terms of the proportion of participants who had stopped bleeding within a specified period of up to 30 minutes of treatment. Only <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> provided data for this comparison. The study found no evidence of a difference between the topical tranexamic acid and control groups at 30 minutes (RR 0.79, 95% CI 0.56 to 1.11; single study; 68 participants) (<a href="./references#CD004328-fig-0007" title="">Analysis 1.2</a>). The quality of this evidence was <i>low</i>. </p> </section> <section id="CD004328-sec-0105"> <h6 class="title">Severity of re‐bleeding: as measured by a) the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation) within 10 days and b) the proportion of patients requiring blood transfusion within 10 days </h6> <p>No studies reported the proportion of patients requiring any further intervention.</p> <p>When comparing oral tranexamic acid with placebo <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a> found no evidence of a difference in the proportion of patients requiring blood transfusion: 5/45 versus 6/44 (RR 0.81, 95% CI 0.27 to 2.48; 89 participants) (<a href="./references#CD004328-fig-0008" title="">Analysis 1.3</a>) (<i>low‐quality evidence</i>). </p> </section> <section id="CD004328-sec-0106"> <h6 class="title">Length of hospital stay in days</h6> <p><a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> reported a significantly shorter stay in the oral tranexamic acid group (mean difference (MD) ‐1.60 days, 95% CI ‐2.49 to ‐0.71; 68 participants). <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a> found no difference (MD 0.40 days, 95% CI ‐0.84 to 1.64; 89 participants) (<a href="./references#CD004328-fig-0009" title="">Analysis 1.4</a>). When we attempted to combine the data from these studies, the heterogeneity was high (I<sup>2</sup>= 85%). </p> </section> <section id="CD004328-sec-0107"> <h6 class="title">Other adverse effects</h6> <p>All five studies recorded 'adverse effects' in a general way. <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> identified no "symptoms which might be taken for general side effects". Two patients (one in each group) experienced small synechiae, likely to be related to the nasal packing rather than the intervention. Three patients in each group in the <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a> study reported that the gel had a 'bad taste' but no serious adverse event was recorded. <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a> reported some complaints of mild nausea and diarrhoea, but these were experienced equally each group. One patient did develop a "a superficial thrombophlebitis of both legs following discharge from hospital”, however it is not reported in which group this occurred. </p> </section> </section> </section> <section id="CD004328-sec-0108"> <h4 class="title">Tranexamic acid versus other haemostatic agents</h4> <p>See <a href="./full#CD004328-tbl-0002">summary of findings Table 2</a>. </p> <p><a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> evaluated this comparison and data were only available for two outcomes. </p> <section id="CD004328-sec-0109"> <h5 class="title">Control of epistaxis: time to stop initial bleeding (as measured by the proportion of patients whose bleeding is controlled within 30 minutes) </h5> <p>When we pooled the data from the three studies the proportion of patients whose bleeding stopped within 10 minutes was significantly higher in the topical tranexamic acid group (70% versus 30%; RR 2.35, 95% CI 1.90 to 2.92, three studies, 460 participants) (<a href="./references#CD004328-fig-0010" title="">Analysis 2.1</a>; <a href="#CD004328-fig-0005">Figure 5</a>). There was no heterogeneity in the pooled analysis (I<sup>2</sup> = 0%). </p> <div class="figure" id="CD004328-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Tranexamic acid versus other haemostatic agent, outcome: 2.1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes)." data-id="CD004328-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Tranexamic acid versus other haemostatic agent, outcome: 2.1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes). </p> </div> </div> </div> </section> <section id="CD004328-sec-0110"> <h5 class="title">Adverse events</h5> <p>There was no difference between the groups in complications (nausea/vomiting and intolerance) and no serious adverse event was observed (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a> did not report adverse events. </p> <p>No data were available for any of our other outcomes.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004328-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004328-sec-0111"></div> <section id="CD004328-sec-0112"> <h3 class="title" id="CD004328-sec-0112">Summary of main results</h3> <p>See <a href="./full#CD004328-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>The primary outcome measure for this review was the effectiveness of tranexamic acid in the control of epistaxis as measured by the proportion of patients who had an episode of re‐bleeding <i>within the first 10 days of treatment</i>. </p> <p>We found moderate‐quality evidence that tranexamic acid probably reduces the risk of re‐bleeding when compared to placebo or no treatment. Tranexamic acid was used in two very different ways in the three studies on which this finding is based: as an oral treatment, given regularly over several days (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>; <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>) and as a 'one‐off' topical intervention at the patients' initial presentation (<a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>). Subgroup analysis to compare the effects of oral and topical tranexamic acid showed a similar effect to the overall result, although for the topical tranexamic acid group the 95% confidence interval included unity. The quality of evidence provided by this single study is low therefore it is uncertain whether or not topical tranexamic acid is effective in stopping bleeding in the period 10 days after a single application. </p> <p>We also measured control of epistaxis in terms of the proportion of participants who had stopped bleeding within 30 minutes of treatment. For the comparison of tranexamic acid versus placebo we found low‐quality evidence from a single study and determined that tranexamic acid may lead to little or no difference (<a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>). This outcome was also addressed in three studies comparing tranexamic acid versus another haemostatic agent (epinephrine/lidocaine combination or phenylephrine) and moderate‐quality evidence indicates that tranexamic acid probably increases the chance of bleeding stopping in the first 10 minutes after application (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). </p> <p>No study specifically sought to identify and report seizures or thromboembolic events (significant adverse effects). </p> <p>No studies reported the proportion of patients requiring any further intervention (e.g. repacking, surgery, embolisation) within 10 days. </p> <p>Blood transfusion requirements were only recorded in one study with no significant differences between the oral tranexamic acid and control groups (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). </p> <p>One study reported a significantly shorter length of hospital stay in the oral tranexamic acid group (<a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a>), while another found no difference (<a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). </p> <p>Five included studies mentioned recording adverse effects but none identified any significant differences between groups. </p> </section> <section id="CD004328-sec-0113"> <h3 class="title" id="CD004328-sec-0113">Overall completeness and applicability of evidence</h3> <p>Whilst the limited amount of evidence identified in this review is applicable to the review question, the paucity of it means that the evidence is far from complete. The identified studies also highlight a clear difference between the two ways in which tranexamic acid has been used: as a short‐term topical treatment and a longer‐term oral one. In neither case is there a clear and unequivocal answer about the merits of tranexamic acid. </p> <p>The adult participants recruited to the studies are representative of those seen in day‐to‐day practice. </p> <p>The definition of 'usual care' encompasses most of the standard treatments used, but such 'usual care' varies around the world and is in a continuous state of evolution as new types of packs and packing materials are introduced. </p> </section> <section id="CD004328-sec-0114"> <h3 class="title" id="CD004328-sec-0114">Quality of the evidence</h3> <p>The body of evidence included in this review (six studies with a total of 692 participants) is insufficient to allow robust conclusions to be drawn. The quality of evidence for the outcomes assessed was moderate or low; we downgraded the evidence because of imprecision and study limitations (risk of bias). </p> </section> <section id="CD004328-sec-0115"> <h3 class="title" id="CD004328-sec-0115">Potential biases in the review process</h3> <p>Three of the most recent included studies took place in Iran (<a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>; <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). Two were conducted by the same research group (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>); however, patient numbers, characteristics and recruitment periods in the three studies were clearly different. </p> <p>The search for relevant studies for this review encompassed all the main databases as outlined in the <a href="#CD004328-sec-0055">Search methods for identification of studies</a> section. The search terms used should have identified all randomised controlled trials comparing the use of tranexamic acid in epistaxis to either placebo or 'usual care'. We do not believe that the methodology of the review is likely to have introduced any bias into the review process. </p> </section> <section id="CD004328-sec-0116"> <h3 class="title" id="CD004328-sec-0116">Agreements and disagreements with other studies or reviews</h3> <p>A number of systematic reviews have evaluated the use of tranexamic acid in patients undergoing nasal surgery but we are only aware of two other systematic reviews of its use in patients with epistaxis (<a href="./references#CD004328-bbs2-0034" title="KamhiehY , FoxH . Tranexamic acid in epistaxis: a systematic review. Clinical Otolaryngology2016;41(6):771‐6. ">Kamhieh 2016</a>; <a href="./references#CD004328-bbs2-0046" title="WilliamsA , BiffenA , PilkingtonN , ArrickL , WilliamsRJ , SmithME , et al. Haematological factors in the management of adult epistaxis: systematic review. Journal of Laryngology and Otology2017;131(12):1093‐107. [DOI: 10.1017/S0022215117002067; PUBMED: 29280698] ">Williams 2017</a>). <a href="./references#CD004328-bbs2-0034" title="KamhiehY , FoxH . Tranexamic acid in epistaxis: a systematic review. Clinical Otolaryngology2016;41(6):771‐6. ">Kamhieh 2016</a> does not appear to have pre‐specified the outcome measures of interest, does not include the studies <a href="./references#CD004328-bbs2-0001" title="AtabakiP , SamareiR , AribiMS , SoheiliA , MehryarHR . A comparative study on the effect of topical phenylephrine with topical tranexamic acid in management of epistaxis. Journal of the Urmia Nursing and Midwifery Faculty2017;15(7):488‐96. ">Atabaki 2017</a>, <a href="./references#CD004328-bbs2-0002" title="PetrusonB . A double blind study to evaluate the effect on epistaxis with oral administration of the antifibrinolytic drug tranexamic acid (Cyklokapron®). Acta Otolaryngologica1974;77(Suppl 317):57‐61. ">Petruson 1974</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>, and provides a narrative description of the studies and the results. The authors do not seem to have noted the additional differences (other than the topical treatment applied at the outset) between the two arms of the <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> study, and the implications of this. <a href="./references#CD004328-bbs2-0046" title="WilliamsA , BiffenA , PilkingtonN , ArrickL , WilliamsRJ , SmithME , et al. Haematological factors in the management of adult epistaxis: systematic review. Journal of Laryngology and Otology2017;131(12):1093‐107. [DOI: 10.1017/S0022215117002067; PUBMED: 29280698] ">Williams 2017</a> identified four of the same randomised controlled trials that are included in our review and drew comparable conclusions, noting the small numbers of participants and study limitations and proposing the need for further studies. A recent UK consensus document reflects these findings and does not recommend the use of tranexamic acid in the management of epistaxis, beyond its use as defined in national guidelines for major haemorrhage (<a href="./references#CD004328-bbs2-0031" title="INTEGRATE (The National ENT Trainee Research Network), National ENT Trainee Research Network. The British Rhinological Society multidisciplinary consensus recommendations on the hospital management of epistaxis. Journal of Laryngology and Otology2017;131(12):1142‐56. ">BRS 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004328-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Process for sifting search results and selecting studies for inclusion." data-id="CD004328-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Process for sifting search results and selecting studies for inclusion.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004328-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004328-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tranexamic acid versus placebo plus usual care or usual care alone, outcome: 1.1 Control of epistaxis: episodes of re‐bleeding over 10 days." data-id="CD004328-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tranexamic acid versus placebo plus usual care or usual care alone, outcome: 1.1 Control of epistaxis: episodes of re‐bleeding over 10 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Tranexamic acid versus other haemostatic agent, outcome: 2.1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes)." data-id="CD004328-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Tranexamic acid versus other haemostatic agent, outcome: 2.1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 1 Control of epistaxis: episodes of re‐bleeding over 10 days." data-id="CD004328-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 1 Control of epistaxis: episodes of re‐bleeding over 10 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 2 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 30 minutes)." data-id="CD004328-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 2 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 30 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 3 Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days." data-id="CD004328-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 3 Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 4 Length of hospital stay." data-id="CD004328-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tranexamic acid versus placebo plus usual care or usual care alone, Outcome 4 Length of hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004328-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/urn:x-wiley:14651858:media:CD004328:CD004328-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_t/tCD004328-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tranexamic acid versus other haemostatic agent, Outcome 1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes)." data-id="CD004328-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tranexamic acid versus other haemostatic agent, Outcome 1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/media/CDSR/CD004328/image_n/nCD004328-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004328-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with nasal haemorrhage (epistaxis)<br/> <b>Setting:</b> inpatients and outpatients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> placebo plus usual care or usual care alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens?</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo plus usual care or usual care alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days</p> <p>All treatments (topical and oral)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.56 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranexamic acid probably leads to fewer re‐bleeding events compared to placebo at 10 days </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/> (376 to 605) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days<br/> Oral treatment only </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/> (0.55 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oral tranexamic acid probably leads to fewer re‐bleeding events compared to placebo at 10 days </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>679 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>496 per 1000<br/> (373 to 652) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days<br/> Topical application (10% gel) only </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.41 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the chance of re‐bleeding in the 10 days after a single topical application of tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>658 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>434 per 1000<br/> (270 to 691) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: time to stop initial bleeding<br/> (proportion of patients whose bleeding is controlled in ≤ 30 minutes) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79 (0.56 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the proportion of patients whose epistaxis was controlled in the first 30 minutes </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>474 per 1000 (336 to 666)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.27 to 2.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>A single study found no evidence of a difference in the proportion of patients needing a blood transfusion </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (37 to 338) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One study reported a significantly shorter stay in the oral tranexamic acid group (MD ‐1.60 days, 95% CI ‐2.49 to ‐0.71; 68 participants). The other study found no evidence of a difference between the groups. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not pool the data due to heterogeneity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: serious or other</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study specifically sought to identify and report our primary outcome, the significant adverse effects of seizure and thromboembolism. All the studies recorded "adverse effects" in a general way and there were no significant differences between groups in the occurrence of the minor adverse effects noted (e.g. mild nausea and diarrhoea, 'bad taste' of gel). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Imprecision: downgraded by one level ‐ small number of studies (or single study) and small number of participants (per study).<br/> <sup>2</sup>Study limitations (risk of bias): downgraded by one level due to study risk of bias (differences in baseline severity of bleeding that could affect the result in <a href="./references#CD004328-bbs2-0003" title="TibbelinA , AustR , BendeM , HolgerssonM , PetrusonB , RundcrantzH , et al. Effect of local tranexamic acid gel in the treatment of epistaxis. ORL; Journal for Oto‐rhino‐laryngology and its Related Specialties1995;57(4):207‐9. ">Tibbelin 1995</a>; selective reporting in <a href="./references#CD004328-bbs2-0004" title="WhiteA , O'ReillyBF . Oral tranexamic acid in the management of epistaxis. Clinical Otolaryngology and Allied Sciences1998;13(1):11‐6. ">White 1988</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tranexamic acid compared to placebo plus usual care or usual care alone for patients with nasal haemorrhage (epistaxis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004328-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with nasal haemorrhage (epistaxis)<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> tranexamic acid<br/> <b>Comparison:</b> other haemostatic agent </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with other haemostatic agent</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with tranexamic acid</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control of epistaxis: episodes of re‐bleeding over 10 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>We could not assess this outcome due to differences between the intervention and control arms (other than the application of tranexamic acid) after the first 10 minutes of treatment in <a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a> and <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a> (see <a href="#CD004328-sec-0074">Included studies</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.35<br/> (1.90 to 2.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>460<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tranexamic acid probably leads to a higher proportion of participants with bleeding controlled within 10 minutes. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>702 per 1000<br/> (568 to 872) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Outcome not assessed.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>We could not assess this outcome due to differences between the intervention and control arms (other than the application of tranexamic acid) after the first 10 minutes of treatment (see <a href="#CD004328-sec-0074">Included studies</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects: serious or other</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study specifically sought to identify and report our primary outcome, the significant adverse effects of seizure and thromboembolism. Five of the studies recorded "adverse effects" in a general way and there were no significant differences between groups in the occurrence of the minor adverse effects noted (e.g. mild nausea and diarrhoea, 'bad taste' of gel). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to study limitations (risk of bias ‐ no blinding) (<a href="./references#CD004328-bbs2-0005" title="SaeediM , ArasiS . Effectiveness of local tranexamic acid on epistaxis control. Iranian Registry of Clinical TrialsApril 2012. ZahedR , MoharamzadehP , Alizadeh ArasiS , GhasemiA , SaeediM . A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial. American Journal of Emergency Medicine2013;31(9):1389‐92. ">Zahed 2013</a>; <a href="./references#CD004328-bbs2-0006" title="ZahedR , Mousavi JazayeriM H , NaderiA , NaderpourZ , SaeediM . Topical tranexamic acid compared with anterior nasal packing for treatment of epistaxis in patients taking antiplatelet drugs: randomized controlled trial. Academic Emergency Medicine2018;25(3):261‐6. ">Zahed 2018</a>). </p> <p><sup>2</sup>Downgraded by one level for imprecision (wide confidence interval). </p> <p><sup>3</sup>Upgraded by one level ‐ large effect size (RR 2.35). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Tranexamic acid compared to other haemostatic agent for patients with nasal haemorrhage (epistaxis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/full#CD004328-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004328-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tranexamic acid versus placebo plus usual care or usual care alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Control of epistaxis: episodes of re‐bleeding over 10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.56, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topical application (10% gel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.41, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 30 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.27, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Length of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tranexamic acid versus placebo plus usual care or usual care alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004328-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tranexamic acid versus other haemostatic agent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Control of epistaxis: time to stop initial bleeding (proportion with bleeding controlled within 10 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.90, 2.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tranexamic acid versus other haemostatic agent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004328.pub3/references#CD004328-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004328.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004328-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004328-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004328-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD004328-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004328-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD004328-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004328-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004328\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004328\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004328\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004328\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004328\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004328.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004328.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004328.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004328.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004328.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729335514"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004328.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729335518"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004328.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eda653a48f4a4',t:'MTc0MDcyOTMzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 